Arista™AH, Medafor's Surgical Hemostatic Technology, Receives Approval for European Market
CE Mark Clears the Way for Rapid Expansion into All Surgical Specialties

Minneapolis, Minn., September 19, 2002 - Medafor, Inc., announced today that its breakthrough surgical hemostat, Arista™ AH, has received CE mark for intra-operative surgical applications. The Company will now actively market to a range of surgical indications in Europe through its recently opened international service center in Munich, Germany.

Medafor CEO Richard Zerban said, “CE certification was a timely achievement that provides Medafor the opportunity to expand the use of its innovative technology throughout the European surgical arena. Countries outside the EU also recognize the CE mark as a compliance standard and permit immediate market entrance.” Product sales of Arista™ AH have commenced through newly signed distribution agreements in Germany, Belgium, France, Italy, Spain, and Greece.

Medafor’s related products have already received Federal Food and Drug Administration (FDA) approval for topical use in the United States. TraumaDEX™ has been cleared for use by doctors and medical services personnel for temporary control of severe bleeding in a variety of trauma and post surgical wounds. HemaDerm™ has been cleared to treat bleeding in dermatological procedures and vascular access sites. Bleed-X™ has been approved for over-the-counter use for cuts, lacerations and abrasions. These products and Arista™ AH are based on Medafor’s MPH™ (Microporous Polysaccharide Hemospheres) technology - a biopolymeric, microporous powder which produces rapid hemostasis in areas of profuse bleeding.

MPH™ is a novel hemostatic technology which, when applied to a bleeding wound site, initiates coagulation within seconds. The particles act as molecular sieves to absorb fluids in the blood, attracting and concentrating proteins and platelets and accelerating the natural clotting cascade. To learn more about MPH™ and its benefits, visit the company’s web site at http://www.medafor.com.

Based in the Twin Cities suburb of Fridley, Medafor, Inc., is a privately held Minnesota corporation founded in 1999 to develop and market applications of its patented, groundbreaking hemostatic technology.

This release may contain forward-looking statements based on current expectations of future events. If underlying assumptions prove inaccurate, or unforeseen risks or circumstances materialize, actual results could vary materially from expectations and projections stated herein. The company assumes no obligation to update any forward-looking statements as a result of new information or future developments. BACK.